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Abstract
Neuromodulator interdependence posits that changes in one or more neuromodulators are compensated by
changes in other modulators to maintain stability in the respiratory control network. Herein, we studied
compensatory neuromodulation in the hypoglossal motor nucleus (HMN) after chronic implantation of
microtubules unilaterally (n = 5) or bilaterally (n = 5) into the HMN. After recovery, receptor agonists or
antagonists in mock cerebrospinal fluid (mCSF) were dialyzed during the awake and non-rapid eye movement
(NREM) sleep states. During day studies, dialysis of the µ-opioid inhibitory receptor agonist [d-Ala2, N-MePhe4,
Gly-ol]enkephalin (DAMGO; 100 µM) decreased pulmonary ventilation (V� i), breathing frequency (f), and
genioglossus (GG) muscle activity but did not alter neuromodulators measured in the effluent mCSF. However,
neither unilateral dialysis of a broad spectrum muscarinic receptor antagonist (atropine; 50 mM) nor unilateral
or bilateral dialysis of a mixture of excitatory receptor antagonists altered V� i or GG activity, but all of these did
increase HMN serotonin (5-HT) levels. Finally, during night studies, DAMGO and excitatory receptor antagonist
decreased ventilatory variables during NREM sleep but not during wakefulness. These findings contrast with
previous dialysis studies in the ventral respiratory column (VRC) where unilateral DAMGO or atropine dialysis
had no effects on breathing and bilateral DAMGO or unilateral atropine increased V� i and f and decreased GABA
or increased 5-HT, respectively. Thus we conclude that the mechanisms of compensatory neuromodulation are
less robust in the HMN than in the VRC under physiological conditions in adult goats, possibly because of site
differences in the underlying mechanisms governing neuromodulator release and consequently neuronal
activity, and/or responsiveness of receptors to compensatory neuromodulators.

NEW & NOTEWORTHY Activation of inhibitory µ-opioid receptors in the hypoglossal motor nucleus
decreased ventilation under physiological conditions and did not affect neurochemicals in effluent dialyzed
mock cerebral spinal fluid. These findings contrast with studies in the ventral respiratory column where
unilateral [d-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO) had no effects on ventilation and bilateral DAMGO or
unilateral atropine increased ventilation and decreased GABA or increased serotonin, respectively. Our data
support the hypothesis that mechanisms that govern local compensatory neuromodulation within the brain
stem are site specific under physiological conditions.
The importance of maintaining a balance between excitatory and inhibitory neuromodulation in neural
networks is illustrated by the severity of pathological conditions such as Parkinson’s disease (44), epilepsy (37),
schizophrenia (40), and depression (38). It is also widely accepted that an imbalance in neuromodulators
contributes to dysfunction in diseases of respiratory control such as sudden infant death and opioid-induced

respiratory depression (10, 13, 17). Accordingly, to develop more effective treatments for these pathologies,
there is a need to develop a better understanding of the fundamental mechanisms that govern the
neuromodulation and thus the excitability of neural networks.
Important studies aiming to better understand the fundamental role of excitatory and inhibitory modulation
have been focused on the neural network that generates respiratory rhythm and/or pattern, which includes a
medullary site critical for rhythm generation, the pre-Bötzinger complex (preBötC; 7, 8). The alterations of
various excitatory neuromodulatory receptors in this region suggested that no single excitatory
neuromodulatory receptor, when blocked, could lead to ventilatory depression in vitro and in vivo. Instead,
changes in ventilation required multiple receptor antagonists simultaneously, which led to the concept of
neuromodulator interdependence whereby perturbations in the activity of one or more neuromodulator
receptors is compensated by changes in other neuromodulators to maintain stable ventilation (7, 8). This
hypothesis has been further tested by unilateral microdialysis of antagonists to excitatory neuromodulator
receptors in the preBötC region of the ventral respiratory column (VRC) of awake and sleeping goats (32–35).
Unexpectedly, VRC dialysis of the broad spectrum muscarinic receptor antagonist atropine (50 mM) increased
pulmonary ventilation (V� i) and breathing frequency (f) during wakefulness and to a lesser extent during nonrapid eye movement (NREM) sleep, with concomitant, large, and local increases in serotonin (5-HT) and
substance P (SP) in effluent dialysate (32). Lower concentrations of atropine alone or in combination with
neurokinin-1 (NK1) and/or 5-HT receptor blockers dialyzed in this same region did not affect V� i but still elicited
compensatory increases in excitatory neuromodulators 5-HT and SP (32–35). These local increases in the
excitatory neuromodulators SP and 5-HT may conceivably compensate for the induced antagonism of excitatory
receptors (32).
Increased activity of inhibitory neuromodulatory receptors in the VRC of awake and sleeping goats does not
elicit local increases in excitatory neuromodulators but still provides another example of compensatory
neuromodulation. For example, dialysis of the µ-opioid receptor agonist [d-Ala2, N-MePhe4, Gly-ol]enkephalin
(DAMGO) led to a dose-dependent decrease in the local, endogenous GABA in the effluent dialysate (20). The
reduced GABA levels were concomitant with transient decreases in V� i with unilateral DAMGO, whereas bilateral
dialysis of 100 µM DAMGO increased V� i and f and increased the variability of V� i (20), indicative of local
neuromodulator compensation for the increased inhibition by the exogenously delivered opioid. Thus,
collectively, the summarized results support the concept of neuromodulator interdependence in respiratory
rhythm- and pattern-generating nuclei such as the preBötC of the VRC (7, 8, 20, 21, 32–35). The mechanism of
compensation is unknown, but the changes in neuromodulators are local; thus compensation may occur within
individual ionic currents of a single neuron. It is also unclear whether these compensatory mechanisms exist at
other sites within the respiratory control system or whether pathophysiological shifts in the balance of
excitation and inhibition in disorders of respiratory control represent failures or exacerbations of such
neuromodulatory compensatory mechanisms.
Accordingly, the objective herein was to determine whether similar mechanisms of compensatory
neuromodulation occur at another site within the neural respiratory control network that has distinctly different
functions and cell composition from those of the VRC, such as the hypoglossal motor nucleus (HMN). Largely
composed of large motor neurons that innervate the genioglossus (GG) muscle, the HMN motor neurons direct
muscular GG contraction during inspiration to maintain a patent upper airway and minimize airway resistance
(41–43). The GG is a main muscle in swallowing behaviors. Abnormal function of the HMN can lead to airway
constriction, reduced airflow, obstructive apneas, and dystussia/aspiration, suggesting that a better
understanding of potential mechanisms of neuromodulator compensation in the HMN has major clinical
relevance, particularly during sleep when hypoglossal muscle activity is reduced from the awake state more than
diaphragm activity (10, 15, 41).

Our overall hypothesis was that mechanisms of compensatory neuromodulation are not uniform throughout the
respiratory control network. Accordingly, since others (10, 13, 48) found that dialysis of various µ-opioid
receptor agonists into the HMN depressed respiratory output and GG muscle activity, we hypothesized that
unilateral and bilateral dialysis of DAMGO in the HMN would depress respiratory output and GG muscle activity
in awake and sleeping goats and would not elicit local changes in neuromodulators In addition, since others
(1, 48) have shown that acetylcholine modulation of the HMN is via the inhibitory M2 receptor and since there
appears to be minimal stimulation of the HMN by 5-HT (15), we hypothesized that dialysis of antagonists to
muscarinic, NK1, and 5-HT receptors would not depress ventilation and there would be no compensatory
increase in neuromodulators.

METHODS
Goats.

Ten adult, female, nonpregnant goats with an average body weight of 44.5 ± 2.6 (SE) kg were housed and
studied in an environmental chamber with a fixed ambient temperature and alternating 12-h light-dark cycles
set between 7 AM and 7 PM. The goats had free access to food and water except for study periods and the 24-h
preceding surgeries. Protocols and procedures utilized in this study were approved by the Medical College of
Wisconsin Institutional Animal Care and Use Committee.

Surgical procedures.

Prior to surgery, the goats were anesthetized with ketamine (intravenous), intubated, and mechanically
ventilated with isoflurane in 100% oxygen throughout surgery. To minimize sensation of pain, flunixin
meglumine (2 mg/kg im) was administered once preoperatively and for 2 days postoperatively. To prevent
infections, ceftriaxone (25 mg/kg iv) in 100-ml saline was administered over 30 min twice daily at 8–12-h
intervals for 3 days starting the morning of a craniotomy surgery. Thereafter, ceftiofur sodium (4 mg/kg im) and
gentamicin (6 mg/kg im) were administered once daily for the remainder of the study period. To minimize
intracranial swelling following the craniotomy, dexamethasone (4 mg/ml iv) was administered three times daily
and tapered for a week following surgery. After surgeries, sites of surgical incisions were treated daily for 7 days
with triple-antibiotic ointment. Rectal temperature (TR), heart rate (HR), and oxygen saturation were
continuously monitored during surgery and at regular intervals over 24 h postsurgery.
Two sterile surgeries were performed separated by 2 wk. For the first, an incision was made in the goat’s neck to
locate the carotid artery, which was subsequently dissected out, elevated to beneath the skin, and sutured to
the overlaying skin before closing the incision. In addition, electroencephalographic (EEG) and
electrooculographic (EOG) electrodes were inserted into the midline cranium and the superior orbital ridge for
subsequent recordings to score wakefulness/sleep during night studies. The electrodes were attached to screws
and secured with dental acrylic, and the wires were pulled through the skin before closure of the incision.
Finally, bipolar electromyographic (EMG) electrodes were implanted into the diaphragm (DIA), abdominal, and
genioglossus (GG) muscles and tunneled to the exterior for recording of inspiratory, expiratory, and airway
muscle activity.
Two weeks later, stainless steel microtubules (70.0-mm length, 1.27-mm OD, and 0.84-mm ID) were chronically
implanted unilaterally (n = 5) or bilaterally (n = 5) into the HMN. An incision bisected the nuchal ligament along
the dorsal midline of the skull and neck, and then a rotary drill was used to create an occipital craniotomy for
visualization of the dura, which, when opened, exposed the dorsal medulla. Obex was the anatomical reference
for micromanipulator-controlled microtubule placement into the HMN, which in goats extends from ~3 mm
caudal to 3.5 mm rostral to obex, 0.5–1.5 mm lateral to the midline, and 2–3.5 mm from the dorsal surface. In
some goats, adjustments in microtubule placements had to be made to avoid blood vessels. Screws were

inserted into the skull to which the microtubules were secured using dental acrylic. Stainless steel stylets slightly
shorter than the microtubules were inserted into the microtubules, and the incisions were sutured closed.
Following the procedure, postoperative monitoring and medications were administered as described above.

Physiological data collection.

Following the second surgery, the goats were allowed a minimum of 2 wk to recover before the initiation of
studies. During this time, the goats were accustomed to the study apparatus and protocol. To obtain ventilatory
data, a custom mask was specially fitted to each animal and during studies secured to their muzzles. A two-way
valve was inserted into the end of the mask, and tubing was attached to inspiratory and expiratory sides of the
valve. The inspiratory tubing was attached to a pneumotachograph connected to a Windaq data-recording
system and used to obtain breath-by-breath inspiratory flow (V� i, l/min), breathing frequency (f,breaths/min),
tidal volume (VT, l/breath), inspiratory (TI) and expiratory (TE) time(s), and inspiratory drive (VT/TI). During
daytime studies, the expiratory tubing was attached to a Tissot spirometer. The expired air was collected at 5min intervals and analyzed for O2 and CO2 concentration for calculation of O2 consumption. Every 30 min of
several studies, arterial blood was withdrawn from a catheterized carotid artery for analysis of pH, Pco2, and Po2.
The arterial catheter line was attached to a transducer to obtain blood pressure (BP) and HR using the Windaq
data analysis system. Respiratory muscle activity was recorded via Windaq using the chronically implanted
electrodes. To determine and score sleep state during night studies, signals from EEG and EOG electrodes were
recorded via Windaq and later scored always by the same investigator. Finally, TR was recorded throughout the
studies herein.
Dialysis probes [Harvard Apparatus (formerly CMA Microdialysis), Holliston, MA] inserted into the microtubules
were 72 mm in length, 70 mm of which is a stainless steel tube and the final 2 mm of which is a semipermeable
membrane (membrane diameter 0.5 mm, 20-kDa cutoff, 3-µl internal volume). Only the 2-mm membrane
penetrated the brain tissue. During studies, the perfusate was either mock cerebrospinal fluid (mCSF: 124 mM
NaCl, 2.0 mM KCl, 2.0 mM MgCl2, 1.3 mM K2PO4, 2.0 mM CaCl2, 11 mM glucose, and 26 mM NaHCO−3HCO3−, pH
7.32 in sterile distilled H2O) alone or mixed with receptor agonist or antagonists described below. The solutions
were prepared in a tonometer flask, warmed to 39°C, and equilibrated with 6.4% CO2 and 12% O2 balance N2. A
syringe pump (Harvard Apparatus) delivered the dialysate to the dialysis probe at a flow rate of 25 µl/min. To
minimize distraction of the goat, the pump was outside of the chamber; thus a 150-cm length of polyethylene
tubing (PE50) was needed to connect the syringe to the probe. The length of the tubing caused a delay of ~20
min between the start of dialysis and the arrival of perfusate at the probe tip. As a result of this delay, the first
15 min of hour 2 of dialysis were omitted from statistical analysis. Moreover, during the initial 15–20 min of hour
3,drug delivery to the tissue would continue as in hour 2. In addition, thereafter, washout of the drug from the
tissue would be time dependent. As a result, the reported ventilatory responses herein would likely reflect these
drug delivery and washout characteristics. To collect effluent dialysate, a short length of tubing was attached to
the outlet end of the probe, which was then attached to a modified cryotube. Separate tubes were used for
effluent collection during each hour of dialysis. The effluent was then aliquoted and frozen at −80°C for
subsequent analyses.
Three continuous hours of dialysis began 60 min after probe insertion. Hour 1 was mCSF alone, hour 2 was mCSF
alone or mCSF mixed with different drugs, and hour 3 was mCSF alone. One dialyzed drug was the µ-opioid
agonist DAMGO at concentrations of 10 or 100 µM, which is over the range and duration others used in dialysis
studies on rats or dogs (29, 36) and the same as in previous studies in the VRC (20). The second drug was 50 mM
atropine, which was at the same concentrations during dialysis into the VRC (21, 32). The third drug study was a
mixture of the 5-HT2 receptor antagonist α-phenyl-1-(2-phenylethyl)-4-piperidine methanol (MDL 11,939; 0.5
mM), the NK1 receptor antagonist spantide (500 µM), and the muscarinic receptor antagonist atropine (5 mM).
These antagonists were the same as used in VRC studies (21, 35). The day studies were completed between 9

AM and 2 PM. Night studies were completed between 7 PM and 2 AM. A minimum of 36 h were allowed
between consecutive studies on individual goats.

Neurochemical analyses.

To measure the amino acids glutamine, glycine, and GABA present in effluent dialysate, reverse phase highperformance liquid chromatography was used as published by Muere et al. with fluorescent detection using a
Waters Resolve C18 column (150 × 3.9 mm) and a fluorescent detector with excitation at 229 nm and emission
at 470 nm; β-alanine internal standard was used with o-phthaldialdehyde derivatization (32). To measure 5-HT
and its metabolite hydroxyindoleacetic acid (HIAA), an identical column was used; however, the potential was
set at 0.6 V vs. an Ag/AgCl reference electrode, and an N-methylserotonin internal standard was used. A
commercially available assay (Assay Designs 900-018, range 9.76–10,000 pg/ml; Enzo Life Sciences) and a
microplate reader at 405 nm were used to determine SP levels. Measurement of norepinephrine, dopamine,
and their metabolites [3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)] was accomplished
by using a Waters µBondapak C18 column (300 × 3.9 mm), a potential setting of 0.65 V vs. Ag/AgCl reference
electrode, and a 2,5-dihydroxybenzylamine hydrobromide internal standard. The minimum detectable values for
our analyses of neurochemicals are as follows: glutamine and glycine, <0.04 µM; GABA, <0.02 µM; 5-HT, <0.01
nmol/l; SP, <6.9 pg/ml; and norepinephrine, dopamine, HIAA, and HVA, <0.02 ng/ml.

Brain stem tissue analyses.

Following euthanasia, the cerebral circulation was isolated to flush the brain stems first with phosphatebuffered saline followed by 4% paraformaldehyde. The brain stems were then extracted, dehydrated in
successive 20 and 30% sucrose solutions, and frozen and serially sectioned at 25-µm thickness in the transverse
plane. One series was used for Nissl (cresyl violet) staining to facilitate measurements of microtubule placement.
Images of Nissl-stained (4,000 dots/in.-scanned images) of the entire microtubule tract were captured (Nikon
Super Coolscan 9000). Image software (Metamorph) was used to calibrate and measure microtubule placement
in millimeters (relative to the midline, the obex, and the ventral medullary surface) near the middle of the
rostral-caudal microtubule damage range.

Data and statistical analyses.

A pump with a known airflow rate was used to calibrate the inspiratory flow signal for breath-by-breath
calculation of V� i, f, VT, TI, TE, and VT/TI, using custom-designed software programs.
The EEG and EOG signals were utilized by a single investigator to score sleep state for each breath for night
studies. Wakefulness was characterized by a high-frequency, low-voltage EEG, with variable EOG activity. NREM
sleep was characterized by a low-frequency (<2 Hz), high-voltage (2–3 times greater than wakefulness) EEG with
absent EOG activity. REM sleep was characterized by a high-frequency, low-voltage EEG, similar to wakefulness
but concurrent with frequent and distinct bursting (>30 µV) in the EOG. For hour 1 of the protocol when mCSF
was dialyzed, the average percentages of time awake and in NREM were 81.8 ± 7.2 and 18.2 ± 6.5, respectively.
For hour 2when 100 µM DAMGO was dialyzed, these percentages were 70.8 ± 4.9 and 28.8 ± 4.1, respectively.
For hour 3, when mCSF was dialyzed, these percentages were 68.8 ± 7.4 and 31.0 ± 7.3, respectively. The
percentages were nearly the same during the studies when the mixture of excitatory receptor antagonists was
dialyzed during hour 2. These values for awake and NREM sleep are comparable to previous studies during
which there was no dialysis (27). Similar to our previous studies, there was minimal/no REM sleep during any
hour of dialysis. EEG and EOG were recorded only in night studies, and these signals did not change during the
periods of drug dialysis.
The EMG signals were zeroed at baseline and then rectified and time averaged, after which the signals were
recalibrated with the assignment of arbitrary peak (1) and baseline (0) values (2). These recalibrated EMG signals

were again rectified and time averaged (2). This processing was necessary because of the absence of known
values and provided a measure of relative magnitude within studies (2). The signals were finally converted to a
.txt file, and a custom-designed program outputted all parameters on a breath-by-breath basis (2).
Individual breath ventilatory and EMG data were averaged into 5- and 15-min bins. To restrict statistical
analyses to stable conditions, statistical treatment was only for the last 15 min of hour 1, the final 45 min of hour
2, and all but the first 5 min of hour 3. For all ventilatory and EMG variables, metabolic rate (V� o2), and TR, a twoway repeated-measures (RM) ANOVA compared each drug study to mCSF alone (1-factor repetition with dose
and time as factors). The interaction P values indicated whether there were statistically significant differences
between mCSF alone and mCSF mixed with drugs. For night studies, interaction term Pvalues from two-way RM
ANOVAs (2-factor repetition, state and time as factors with Holm-Sidak post hoc test used when appropriate)
performed on 15-min bins alone were used to determine the effect of sleep state on ventilatory variables. These
statistical analyses were on absolute values for each variable and again after normalizing each variable
during hours 2 and 3 of the protocol to the variable over the last 15 min of hour 1. Variability in all ventilatory
parameters was quantified using the coefficient of variation (CV). The CV was determined for all breaths during
5-min intervals. A two-way RM ANOVA (with dose and time as factors) was used to determine whether
significant interactions occurred as a result of dialysis (Holm-Sidak post hoc test used where appropriate).
For statistical analyses of neurochemical data, two-way RM ANOVAs (1-factor repetition, dose and time as
factors) were used. The P values of the interaction term of ANOVA indicated whether the effect on effluent
neurochemical concentration over time of antagonist dialysis was significantly different from that of the timecontrol studies. This analysis was performed for SP, 5-HT, glutamate, glycine, GABA, dopamine, and
norepinephrine.

RESULTS
Placement of microtubules.

In Fig. 1, left, are representative transverse sections and graphical sketches of multiple rostrocaudal levels of the
goat medulla, in which the location of the distal end of the histologically identified microtubule tract is shown
for each goat (represented by number). On the right are shown Nissl-stained sections from four different goats
in which the disrupted tissue indicates the site of microtubule implantation. The tissue damage shown on
the right likely reflects a combination of microtubule and dialysis probe damage, tissue adherence during
microtubule removal postmortem, and loss of structural support during processing. Even though the 1.27-mmwide microtubule potentially destroyed the nucleus at the insertion site, drugs would diffuse rostrally and
caudally from the dialysis probe (inserted 2 mm beyond the distal end of the microtubule). We did not measure
diffusion of the drugs in this study, but on the basis of measurements described previously (20, 21) we
conservatively estimate diffusion of 0.25 mm from the 1-mm-wide probe, which represents a minimal estimate
of the affected brain stem region in each individual goat. On the basis of calculations of others (29) on drug
diffusion in rats, it is likely that our estimates of diffusion indicated that the drugs were dialyzed into but were
not restricted to the HMN.

Fig. 1.Left: representative transverse sections of the goat medulla, at obex (0.0), 1.0 mm rostral (+1.0) to obex, 2.0 mm
rostral (+2.0) to obex, and 4.0 mm rostral (+4.0) to obex, in which the location of the distal end of the histologically
identified microtubule tract is shown for each goat (represented by number). Medial-lateral and dorsal-ventral coordinates
on the axes are given in mm. Right: Nissl-stained sections from four different goats in which the disrupted tissue indicates
the microtubule tracts. The dialysis membrane extended 2 mm beyond (ventrally) the microtubule. As detailed in the text,
it is likely that for each goat, the dialyzed drugs diffused to a part of the HMN but that diffusion was not restricted to this
nucleus. AP, area postrema; CN, cuneate nucleus; ECN, external cuneate nucleus; FTL, lateral tegmental field; G, gracile
nucleus; HP, nucleus praepositus hypoglossi; INT, nucleus intercalatus; IO, inferior olivary complex; IV, trochlear nucleus;
LRN, lateral reticular nucleus; NA, nucleus ambiguus; NTS, nucleus tractus solitarii; nX, vagus nerve; nXII, hypoglossal nerve;
P, pyramidal tract; R, raphe nucleus; RB, restiform body; RFN, retrofacial nucleus; 5SP, spinal trigeminal nucleus; 5ST, spinal
trigeminal tract; TS, tractus solitaries; V, vestibular nucleus; X, dorsal motor nucleus of the vagus; XII, hypoglossal nucleus.

Effects of DAMGO dialysis in the HMN.

Unilateral dialysis of 10 µM DAMGO during the day did not significantly (P > 0.05) change any ventilatory
variable compared with control values obtained during unilateral dialysis of only mCSF (2-way RM ANOVA, time
and dose as factors), either when the data were expressed in absolute values or when they were normalized to
control (n = 8). However, unilateral 100 µM DAMGO dialyzed during the day significantly decreased V� i (P =
0.016) and significantly increased TE (P < 0.05) during and after DAMGO dialysis (2-way RM ANOVA, time and
dose as factors; n = 8). This difference was apparent in the absolute values of V� i and when V� i was normalized to
control dialyses (Fig. 2). On the other hand, f during DAMGO dialysis significantly differed from mCSF when
expressed as absolute values but not when normalized (Fig. 2). Unilateral dialysis of 10 and 100 µM DAMGO did
not significantly alter absolute or normalized VT, TI, or VT/TI.

Fig. 2.When data during and after unilateral (Unilat) 100 µM [d-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO) dialysis are
expressed as a percentage of the final 15 min of the preceding hour of mock cerebrospinal fluid (mCSF) dialysis, ventilation
(V� i, P = 0.016; A) was lower but breathing frequency (P ≥ 0.249; B) and tidal volume (VT, P = 0.909; C) were not different
from dialysis of mCSF for 3 h (n = 8). ○, Studies during which mCSF was dialyzed for all 3 h; ●, studies during which 100 µM
DAMGO was dialyzed between 60 and 120 min (DAMGO dialysis period indicated by the horizontal solid line). The x-axis
values are time from the start of 180 min of dialysis. Data are means ± SE; br/min, breaths/min. F and P values were
obtained from two-way repeated-measures ANOVA (time and dose as factors).

The EMG recordings suggested that unilateral dialysis of 100 µM DAMGO depressed GG activity compared with
dialysis of mCSF alone (Fig. 3). Indeed, analysis of the integrated EMG (area under the curve) indicated that
compared with mCSF dialysis, unilateral dialysis of 100 µM DAMGO significantly (P< 0.001) decreased GG muscle
activity (Fig. 4A; 2-way RM ANOVA, dose and time as factors; n = 8). However, dialysis of 100 µM DAMGO did
not significantly (P = 0.809) alter diaphragm activity compared with dialysis of mCSF alone (Fig. 4B). Unilateral
100 µM DAMGO dialysis also significantly (P ≤ 0.012) decreased absolute values of V� o2and HR, but did not
significantly (P ≥ 0.05) alter TI, VT/TI, TR, BP, arterial partial pressure of CO2 (PaCO2PaCO2), or PaO2PaO2 (2-way
RM ANOVA, time and dose as factors). Neither 10 µM nor 100 µM DAMGO dialysis significantly (P ≥ 0.05)
increased the variability of any ventilatory parameter (calculated as the CV within each 5-min bin for each dose
of DAMGO).

Fig. 3.Visual inspection of raw ventilatory and electromyographic data tracings before (A) and during (B) unilateral 100 µM
[d-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO) dialysis revealed that ventilation and genioglossus muscle activity were
decreased by DAMGO dialysis. It is also evident that there were no major DAMGO-induced changes in heart rate, arterial
blood pressure, or diaphragm and abdominal activity. Most of the goats chewed the abdominal electrodes, rendering them
dysfunctional; thus insufficient data were obtained to determine whether any treatment significantly altered abdominal
muscle activity. However, the data in this figure are from a goat in whom the abdominal electrodes remained functional,
and it appears that DAMGO did not affect activity of this muscle.

Fig. 4.Unilateral (Unilat) dialysis of 100 µM [d-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO; n = 8) during daytime studies
significantly (P< 0.001) decreased genioglossus (GG) muscle activity (A) but did not change (P = 0.809) diaphragm (DIA)
muscle activity (B; n = 8). ●, Studies during which 100 µM DAMGO was dialyzed during hour 2; ○, studies during which mock
cerebrospinal fluid (mCSF; n = 8) was dialyzed for 3 h. The x-axis indicates time from start of 180-min dialysis studies
(horizontal solid line indicates time of 100 µM DAMGO dialysis). Data (means ± SE) are presented as a percentage of control
using the last 15 min of hour 1 mCSF dialysis as control values. F and P values were obtained from two-way repeatedmeasures ANOVA (time and dose as factors). *Time periods when a significant depression of GG activity occurred.

Absolute values for the awake state at night were generally significantly (P < 0.05) higher than during NREM
sleep. However, the effect of unilateral DAMGO dialysis did not differ between awake and NREM sleep. This
conclusion is based on finding that the percent change in V� i, f, and VT did not differ between awake and NREM
sleep when data during and after DAMGO dialysis were normalized to values over the last 15 min before dialysis
of 10 µM (Fig. 5) or 100 µM DAMGO (2-way ANOVA, state and time as factors). Moreover, using one-way
ANOVA (time as factor), V� i, f, and VT did not change over time during dialysis of DAMGO in the awake state (Fig.
5). However, f (P < 0.013) and, to a lesser extent, V� i and VT (P = 0.067 and 0.084, respectively) decreased during
and after dialysis of 10 µM DAMGO (Fig. 5). Dialysis of 100 µM DAMGO did not result in a similar timedependent decrease in V� i, f, and VT in the awake or NREM states (P > 0.05, data not shown).

Fig. 5.When data during and after unilateral 10 µM [d-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO; n = 8) dialysis are
expressed as a percentage of the final 15 min of the preceding hour of mock cerebrospinal fluid dialysis (n = 8), there were
no significant (P ≥ 0.771) interaction terms for ventilation (V� i; A), breathing frequency (f; B), or tidal volume (VT; C) as
reported by two-way repeated-measures ANOVA comparing non-rapid eye movement (NREM) sleep (○) and night awake
states (●; state and time as factors, F and P values at top left of each panel). Dialysis of 10 µM DAMGO did significantly (P =
0.009) depress fduring the NREM state but did not alter V� i or VT or any ventilatory variable during the night awake state (P ≥
0.171; 1-way repeated-measures ANOVA with time as factor; F and P values for the night awake state at top right and
NREM state bottom right of each panel). The x-axis is time from start of dialysis in 180-min dialysis studies (horizontal solid
line indicates period of dialysis); br/min, breaths/min.

There were no significant (P ≥ 0.992) interaction terms for V� i, f, or VT comparing bilateral dialysis of 100 µM
DAMGO to bilateral dialysis of mCSF (2-way RM ANOVA, dose and time as factors; n = 5). However, bilateral
dialysis of 100 µM DAMGO significantly (P ≤ 0.008) decreased f and VT over time (P value of time factor from 2way RM ANOVA), but V� idid not differ significantly over time (P = 0.992) between bilateral DAMGO and mCSF
dialysis (Fig. 6). During the hour of and the hour after unilateral and bilateral dialysis of 10 and 100 µM DAMGO
during the day, 5-HT, SP, glutamate, norepinephrine, dopamine, glycine, and GABA in the effluent mCSF did not
differ from studies in which only mCSF dialyzed.

Fig. 6.When data during and after bilateral (Bilat) 100 µM [d-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO) dialysis (n = 5) are
expressed as a percentage of the final 15 min of the preceding hour of mock cerebrospinal fluid (mCSF) dialysis, there was
no significant (P ≥ 0.990) interaction between dose and time (2-way repeated-measures ANOVA, dose and time as factors)
for ventilation (V� i; A), breathing frequency (f; B), or tidal volume (VT; C) from 3 h of mCSF dialysis (n = 4). However, bilateral
100 µM DAMGO dialysis significantly decreased f (P = 0.008) and VT (P < 0.001) over time (P values from time factor of 2way repeated-measures ANOVA). Studies during which 100 µM DAMGO was dialyzed from 60 to 120 min are indicated by ●
(horizontal solid line indicates period of DAMGO dialysis). Data are means ± SE; br/min, breaths/min. F and P values were
obtained from two-way repeated-measures ANOVA (time and dose as factors).

Effects of unilateral 50 mM atropine dialysis in the HMN.

When values during and after unilateral dialysis of 50 mM atropine into the HMN of awake goats were
normalized to values before atropine dialysis, there were no significant (P ≥ 0.176) differences in V� i, f, or VT (Fig.
7) compared with dialysis of mCSF alone (2-way RM ANOVA, time and dose as factors; n = 8). However, when a
comparison was made of the absolute values before, during, and after atropine dialysis, f was significantly (P <
0.05) increased by atropine. Irrespective of comparisons of absolute or normalized data, there were no
significant (P ≥ 0.225) effects of 50 mM atropine dialysis on GG and DIA muscle activity, TE, TI, VT/TI, V� o2, HR, BP,
TR, PaCO2PaCO2, or PaO2PaO2 (2-way RM ANOVA, dose and time as factors). Unilateral dialysis of 50 mM
atropine significantly (P < 0.001) increased 5-HT (Fig. 8) but did not significantly (P ≥ 0.093) alter norepinephrine,

dopamine, glycine, GABA, or glutamate in effluent dialysate compared with dialysis of mCSF alone (2-way RM
ANOVA, time and dose as factors).

Fig. 7.Unilateral (Unilat) dialysis of 50 mM atropine during the day (n = 6) did not significantly (P ≥ 0.176) alter ventilation
(V� i; A), breathing frequency (f; B), or tidal volume (VT; C) compared with dialysis of mock cerebrospinal fluid (mCSF) alone
(n = 8). ○, Studies during which mCSF alone was dialyzed for 3 h; ●, studies during which 50 mM atropine was dialyzed from
60 to 180 min (horizontal solid line indicates period of atropine dialysis). F and P values were obtained from two-way
repeated-measures ANOVA with drug and time as factors. Data are means ± SE expressed as percentage of control (using
the last 15 min of hour 1 mCSF dialysis as control values); br/min, breaths/min. The x-axis indicates time from start of 180
min of dialysis.

Fig. 8.Serotonin (5-HT) was significantly (*P < 0.001) increased in hours 2and 3 of 50 mM atropine dialysis studies (n = 6)
compared with dialysis of mock cerebrospinal fluid (mCSF) alone. Unilat, unilateral. The x-axis indicates the period of

dialysis, and data are means ± SE. Fand P values were obtained using two-way repeated-measures ANOVA analysis with
time and drug as factors.

Effects of dialysis of a mixture of muscarinic, 5-HT, and NK1 receptor antagonists in the
HMN.

There were no significant (P ≥ 0.153) changes in V� i, f, or VT(Fig. 9) in response to unilateral daytime dialysis of a
mixture of antagonists to muscarinic (5 mM atropine), 5-HT2A (0.5 mM MDL 11,939), and NK1 (500 µM spantide)
receptor agonists (2-way RM ANOVA, dose and time as factors). Similarly, GG and DIA muscle activity, TE, TI,
VT/TI, V� o2, TR, HR, BP, TR, PaCO2 (2-way RM ANOVA, dose and time as factors) were not altered by unilateral
daytime dialysis of the excitatory antagonist mixture. This lack of a drug effect was apparent irrespective of
comparing absolute or normalized data. We also found no significant (P ≥ 0.435) interaction between state
(awake vs. NREM) and time (2-way RM ANOVA) during antagonist mixture dialysis at night for V� i, f,or VT (Fig. 9).
Analysis by one-way ANOVA (time as factor) indicated that there were also no significant (P ≥ 0.300) timedependent effects of antagonist mixture dialysis on V� i or fduring the night awake or NREM states (Fig. 10). Oneway ANOVA also indicated that VT was not altered (P = 0.715) at night while in awake state but VT was
significantly (P = 0.005) decreased during NREM sleep. During the hour of and the hour after dialysis of the
mixture of antagonists to excitatory receptors, 5-HT, SP, norepinephrine, dopamine, glutamate, GABA, and
glycine levels did not differ significantly (P ≥ 0.116) from the periods when mCSF alone was dialyzed (data not
shown).

Fig. 9.Unilateral (Unilat) dialysis of a mixture of antagonists (n = 7) to muscarinic receptors (5.0 mM atropine), neurokinin-1
(NK1) receptors (500 µM spantide), and serotonin 2A (5-HT2A) receptors [0.5 mM α-phenyl-1-(2-phenylethyl)-4-piperidine
methanol (MDL 11,939)] did not significantly (P ≥ 0.153) alter ventilation (V� i; A), breathing frequency (B), or tidal volume

(VT; C) compared with dialysis of mock cerebrospinal fluid (mCSF) alone (n = 8). ○, Studies during which mCSF alone was
dialyzed for 3 h; ●, studies during which the antagonist cocktail was dialyzed during hour 2 (60–120 min). F and Pvalues
were obtained using two-way repeated-measures ANOVA (dose and time as factors), and data are means ± SE (expressed as
percentage of control with the last 15 min of hour 1 mCSF dialysis used as control values); br/min, breaths/min. The x-axis
indicates time from start of 180-min dialysis.

Fig. 10.Unilateral nighttime dialysis of a mixture of antagonists (n = 5) to muscarinic receptors, neurokinin-1 (NK1) receptors,
and serotonin 2A (5-HT2A) receptors [5.0 mM atropine, 500 µM spantide, and 0.5 mM α-phenyl-1-(2-phenylethyl)-4piperidine methanol (MDL 11,939)] did not result in any significant (P ≥ 0.435) interactions between sleep state and time for
ventilation (V� i; A), breathing frequency (f; B), or tidal volume (VT; C) using two-way repeated-measures ANOVA (state and
time as factors). The antagonist mixture did not significantly (P ≥ 0.715) alter V� i or f in either the night awake (●) or nonrapid eye movement (NREM) sleep (○) state; however, VT was significantly (P = 0.005) depressed in the NREM sleep state,
but not in the night awake (P = 0.197) state. One-way repeated-measures ANOVA (with time as factor) was used to
obtain F and P values for each state. The x-axis indicates time from start of 180-min dialysis studies, and the horizontal solid
line indicates period of antagonist cocktail dialysis (60–120 min); br/min, breaths/min.

DISCUSSION
Our overall hypothesis was that mechanisms of compensatory neuromodulation are not uniform throughout the
respiratory control network. Accordingly, since others (10, 13, 48) found that dialysis of various µ-opioid
receptor agonists into the HMN depressed respiratory output and GG muscle activity, we hypothesized that
unilateral and bilateral dialysis of DAMGO in the HMN would depress respiratory output and GG muscle activity
in awake and sleeping goats and would not elicit local changes in neuromodulators. Our findings support this

hypothesis. In addition, since others (1, 48) have shown that acetylcholine modulation of the HMN is via the
inhibitory M2 receptor and since there appears to be minimal stimulation of the HMN by 5-HT (15), we
hypothesized that dialysis of antagonists to muscarinic, NK1, and 5-HT receptors would not depress ventilation
and there would be no compensatory increase in neuromodulators. Our findings support the ventilatory but not
the neurochemical part of these hypotheses.

Concept of neuromodulator interdependence.

The neural circuitry controlling ventilation is modulated largely through G protein-coupled metabotropic
receptors to determine the network excitability and stability (7, 8). Doi and Ramirez tested the concept of
neuromodulator interdependence where changes in one or more neuromodulators are compensated for by
changes in other modulators to maintain stability in the respiratory control network (7, 8). Subsequent studies
support this concept as compensatory neuromodulation was elicited by dialysis of agonists/antagonists in the
respiratory rhythm/pattern-generating VRC of awake and sleeping goats (20, 21, 32–35). The objective herein
was to study this concept as it applies to the motor neuron-rich HMN, focusing on effects of activating µ-opioid
receptors (DAMGO) or inhibiting muscarinic (atropine), neurokinin-1 (spantide) and select serotonergic
receptors (5-HT2A; MDL 11,939).
Compensatory neuromodulation in the HMN could occur through several different neuromodulators. For
example, 5-HT (14–16, 50–52) has excitatory effects through 5-HT2Areceptors and inhibitory effects through
presynaptic 5-HT1Breceptors (46, 47). Acetylcholine (ACh) in adult mammals has an inhibitory effect through the
type 2 (M2) muscarinic receptor (1, 23), which is dominant over the nicotinic ACh receptors that excite the HMN
(22). Norepinephrine modulates excitability of HMN through presynaptic α1-adrenergic receptors (15), indirectly
by potentiating the excitatory effects of glutamate when coreleased onto motor neurons (3, 15). Antagonists to
GABA (23) and glycine (31) receptors administered to the HMN result in robust increases in GG activity
indicating a significant role of inhibitory amino acids in regulating tonic GG activity (23, 31). In addition, opioids
depress ventilation through G-protein inwardly rectifying potassium channels and voltage-dependent
Ca2+channels (30). However, opioids can also have excitatory effects by inhibition of nonopioid inhibitory
interneurons or by receptor subtypes that cause opposite effects on voltage-sensitive K+ and Ca2+ channels that
cause hyperpolarization (4–6, 45). Indeed, conformational changes in opioid receptors cause coupling to
inhibitory G proteins when exposed to high opioid concentration, whereas the same receptor subtype might
switch to a stimulatory G protein during exposure to low opioid concentrations (11, 49).
Opioids modulate neural activity throughout the central nervous system, including the preBötC and HMN
(10, 18, 20, 48). The effects of opioid administration in the preBötC, critical for the generation of respiratory
rhythm and pattern (18, 21), have been equivocal, where some studies found breathing increases (20, 36),
breathing decreases (28, 29), or no effect (18, 20). Similarly, there are differences between studies on
respiratory effects of opioids delivered to the HMN. In rodents, the dominant effect of opioids is to reduce the
amplitude of hypoglossal activity suggesting that there would be a reduction in tidal volume but not breathing
frequency (10, 24). In awake goats, opioids delivered to the HMN also decreased hypoglossal muscle activity,
which did not significantly decrease tidal volume, but there was an increase in expiratory time and decrease in
breathing frequency. The cause of the decreased frequency is unclear, but it is possible that the DAMGO dialysis
centered on the HMN may have diffused more widely than expected (see Caveats and limitations) and reached
more lateral regions including but not limited to the nucleus of the solitary tract (NTS), a nucleus critical for
integrating peripheral afferent information and cardiorespiratory control (12). Opioids injected directly into the
NTS of anesthetized rats slowed respiratory frequency and significantly altered heart rate (12), which might help
explain the decreases in respiratory frequency and heart rate observed herein.

Differences between sites in respiratory effects of opioids might be due to differences in compensatory
neuromodulation. Dialysis of 100 µM DAMGO unilaterally into the VRC resulted in a mild and transient decrease
in V� i, and bilateral DAMGO increased breathing (20). Concomitant with these effects was a decrease in local
GABA (20), which may have compensated for the opioid-mediated depression. Herein we found that both
unilateral and bilateral dialysis of DAMGO into the HMN decreased V� i without concomitant changes in measured
neuromodulators. These results are consistent with compensatory neuromodulation in the VRC but not in the
HMN.
To our knowledge, the only other study finding increased release of neuromodulators during opioid dialysis into
the HMN was by Skulsky et al., who found a dose-dependent increase in ACh in the effluent mCSF during dialysis
of morphine into the HMN of anesthetized rats (48). Skulsky et al. speculated that the ACh increase was
secondary to disinhibition by opioid receptors on GABAergic neurons controlling ACh release from hypoglossal
motoneurons (48). This response would not be compensatory as the increased ACh would add to and/or could
be the mechanism by which opioids depress neuronal activity. This ACh increase appears unique to medullary
neurons as dialysis of opioids into nuclei rostral to the brain stem decreases ACh release (9, 25, 39).
Since ACh modulation of the HMN is via the inhibitory M2 receptor (22, 26), it could be expected that atropine
dialysis into the HMN would increase breathing. However, there was an increase in 5-HT during atropine dialysis
that may have offset the M2 atropine disinhibition through stimulation of 5-HT1B receptors, which are inhibitory
to breathing (15). It is likely that the increased 5-HT minimally stimulated breathing as others have shown that 5HT stimulation through the 5-HT2A receptor is minimal.

Significance of the present findings.

Since we used the same model and microdialysis protocol as in our previous VRC studies, we can compare
physiological and neurochemical responses to neuromodulatory perturbations in the VRC and HMN. Significant
differences noted particularly in the effects of dialysis of DAMGO included 1) ventilatory instability only at the
VRC, 2) decreased V� o2 and HR only at the HMN, 3) marked hyperpnea during bilateral dialysis only at the VRC,
and 4) absence of measured neurochemical compensation to DAMGO only at the HMN. The site differences in
physiologic responses could all be due to a site difference in compensation by an excitatory neuromodulator.
Alternatively, the site differences in physiologic responses could be due to differences in effects of increased
inhibition/decreased excitation in a rhythm-generating network (VRC) vs. a site of motoneurons
(HMN; 19, 53, 54). Finally, the differences in effects between this and our previous studies may not reflect only
VRC vs. HMN differences because there may have been diffusion of drugs to adjacent nuclei that, for example,
decreased V� o2 and HR in this but not in previous studies. Irrespective of the mechanism, site differences in
physiologic and neuromodulator responses lead to the conclusion previously made by Skulsky et al. that the
existence of these differences “emphasizes the need to characterize opioid effects throughout the widely
distributed neural networks that regulate sleep and breathing” (48).
Also significant are findings that neuromodulator compensation is relatively less robust in the HMN. In other
words, compensatory neuromodulation does not appear to be uniform across as least two critical sites in the
ventilatory control network. It appears that mechanisms that maintain a patent airway are less well protected
against opioid depression than the respiratory rhythm- and pattern-generating network, which would seem
important to obstructive sleep apnea.
Also significant are findings that DAMGO and the mixture of antagonists to receptors of excitatory
neuromodulators depressed components of the ventilatory control system during NREM sleep but not at night
in the awake state (Figs. 5 and 10). These data are consistent with previous findings showing state-dependent
difference in compensatory neuromodulation in the VRC (21, 32).

Finally, it is significant that dialysis of 50 mM atropine into the HMN increased 5-HT in the effluent mCSF
virtually as much as dialysis into the VRC. This finding suggests that the composition of cells and the function of
the nucleus are not strict determinants of changes in neuromodulators to compensate for presumed alterations
in effects of endogenous neuromodulators. As explained earlier, the same change in 5-HT might result in
compensation at both sites by activating two different 5-HT receptors (20, 21, 32–35). This compensatory 5-HT
response is thus very robust, as also indicated by findings that dialysis of 50 mM atropine into the VRC was state
independent, occurring to the same extent during awake, asleep, and anesthetized states (21, 32).

Caveats and limitations.

The limitations of our model and experimental protocol have been discussed in detail in previous articles
(20, 21, 32–35). Nevertheless, we point out that even though the HMN was targeted for microtubule placement,
the need to avoid blood vessels on the surface of the brain stem and/or surgical complications resulted in
variation in placement of the microtubules (Fig. 1). However, the uniformity among goats in the decrease in GG
muscle activity during dialysis of DAMGO provides evidence that the HMN was indeed perfused. The range of
diffusion of drugs from the dialysis probe means that we may have affected other nuclei outside the HMN; thus
it is possible that the effects on ventilation, V� o2, and HR may have been caused in part by DAMGO effects
outside the HMN. Another limitation is that we cannot measure all the potential neurochemicals in effluent
dialysate; thus we could have missed changes in other neuromodulatory molecules. In addition, some
neuromodulators might be metabolized rapidly, only released transiently, or degraded in the tubing and
collection vials; thus the concentration in the effluent mCSF likely will not exactly represent the neuromodulator
at the tissue level.

Conclusions.

We conclude that overall the mechanisms of compensatory neuromodulation are less robust in the HMN than in
the VRC conceivably because of site differences in 1) mechanisms through which neuromodulator perturbations
alter neuronal activity and/or 2) responsiveness of receptors to compensatory neuromodulators.
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